Today's Health Winners and Losers
Shares of Laserscope (LSCP) were among the worst-performing health-related stocks Monday, slumping 13% after the medical device company's first-quarter results missed Wall Street's expectation.
The company earned $2.8 million, or 12 cents a share, on revenue of $32 million. The results included stock-based compensation costs of 2 cents a share. Analysts polled by Thomson First Call expected earnings of 17 cents a share and revenue of $34.9 million. During the year-earlier quarter, the company earned $5 million, or 22 cents a share, on revenue of $28.2 million.
Laserscope continues to project full-year earnings of 72 cents to 75 cents a share, excluding stock-based compensation costs. Analysts project earnings of 79 cents a share. Shares were trading down $3.05 to $20.71.
NeoPharm (NEOL) fell 6% after the biotechnology company said it slashed its workforce by 23%. The move, which was announced Friday evening, is designed to cut annual expenses by about $7 million. "The goal of this program is to balance and achieve efficiencies which adequately support the company's business strategy," the company said. About half of the savings will be realized during 2006, NeoPharm said. Shares were down 44 cents to $7.55.Shares of Natural Alternatives (NAII) jumped 17% after the nutritional supplements company posted a big jump in third-quarter earnings. The company earned $621,000, or 9 cents a share, up from $277,000, or 4 cents a share, a year earlier. Revenue rose to $23.3 million from $22.5 million. The results were helped by the company's recent acquisition of Real Health Laboratories, which added $2.7 million in sales. Looking ahead, Natural Alternatives sees fourth-quarter revenue of $33 million. During the year-earlier period, the company recorded revenue of $24.7 million. Shares recently advanced $1.41 to $9.86. Par Pharmaceutical (PRX) shares rose modestly after the company posted in-line first-quarter earnings on better-than-expected revenue. The company earned $8.4 million, or 24 cents a share, on revenue of $173.8 million. Analysts expected earnings of 24 cents a share and a top line of $145.7 million. During the year-earlier period, the company recorded earnings from continuing operations of $2.7 million, or 8 cents a share, on revenue of $97.5 million. "Par significantly improved its financial performance despite the continued investment necessary to build its branded pharmaceutical organization and its first brand," the company said. Shares were trading up 16 cents to $25.91.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV